Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,139.83 +60.97 (+0.75%) Bitcoin USD
63,949.58 -945.25 (-1.46%) CMC Crypto 200
1,331.08 -65.46 (-4.69%)
ABIONYX Pharma SA (ABNX.PA)
| Previous close | 1.0180 |
| Open | 1.0200 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 1.0000 - 1.0300 |
| 52-week range | 0.9100 - 2.1600 |
| Volume | |
| Avg. volume | 52,192 |
| Market cap | 32.917M |
| Beta (5Y monthly) | -0.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1100 |
| Earnings date | 11 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
PARIS, April 10, 2024--Regulatory News: ABIONYX Pharma (Paris:ABNX)
Business WireABIONYX Pharma - Bpifrance Supports the Development of CER-001 in Ophthalmology With a Nearly €1 Million Non-dilutive Innovation Grant
TOULOUSE, France & LAKELAND, Mich., March 14, 2024--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible) (Paris:ABNX), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, announces a nearly €1 million innovation grant from Bpifrance. The aim of this grant is to support the development of drug candidate CER-001 in the treatment of a severe indication in ophthalmology.
Business WireABIONYX Pharma Announces Its 2023 Full-Year Financial Results
TOULOUSE, France & LAKELAND, Mich., March 11, 2024--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, today announced its 2023 full-year financial results as approved by the full Board of Directors and an update on the activity to date. The audit procedures on the consolidated financial statements have been completed. T
